The Influence of Intranasal Oxytocin on Communication
Study Overview
Detailed Description
Oxytocin is a naturally occurring hormone, commonly known for its role in social approach, bonding, and trust. The present study is designed to investigate whether and how oxytocin may affect communication outcomes--specifically, by influencing trust of people presenting opinions that participants disagree with.
Healthy adult volunteers will intranasally administer 24 IU of oxytocin at one visit and placebo (saline) solution at another visit. Participants will then view photos of speakers presenting opinions on various socio-political issues which the participants disagree with. Participants will complete questions about their psychological reactions (e.g., anger, receptiveness) to the opinions presented. After reporting on their receptiveness to the opposing opinions, participants will begin the attentional tasks. In the attentional tasks, participants will be seated in front of a computer while an eyetracker records their eye movements and attentional gaze. First, participants will view two images presented simultaneously at either ends of the computer screen; each image pair will depict a a) baby and a food, b) baby and an attractive opposite sex target, or c) food and an attractive opposite sex target. Next, participants will view a series of images exclusively depicting one attractive opposite-sex target at a time; attentional bias away from faces and towards bodies (indicative of short-term mating interest; Bolmont, Cacioppo, & Cacioppo, 2014) will be tracked. After each photograph has been viewed for a fixed duration, the participant will answer a question assessing their likelihood of engaging in a one-night stand with the person pictured. After this second part of the task, we will gather saliva samples via passive drool collection. These samples will be later assayed for testosterone. Next participants will complete a measure of visual attention in which they will identify target stimuli (e.g. letters) on a computer screen via keyboard press.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T1Z4
- Kenny Psychology Building
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy adult volunteers
Exclusion Criteria:
- Currently have a diagnosed mental illness or are in psychiatric or psychotherapeutic treatment.
- Are taking endocrinologically or psychoactive drugs (e.g. psychotropic drugs such as antipsychotics, antidepressants, sedatives, or sleeping pills)
- Are taking anti-hypertensive drugs or drugs with QTc prolongation
- Abuse drugs or alcohol
- Suffer from any significant medical illness, such as heart disease/cardiovascular disease, kidney disease, endocrinological disorders, or neurological disorders.
- Are not found to be physically healthy after a required prescreen questionnaire created by a doctor
- Allergic to preservatives (e.g. paragons) found in nasal sprays
- Pregnant/breastfeeding
- Are currently involved in other clinical studies in which drugs are administered.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental
These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
|
Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
Other Names:
|
|
Placebo Comparator: Control - Placebo
These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
|
Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Communication Outcomes
Time Frame: 60-90 minutes
|
Participants will answer a series of questions regarding their reactions (e.g., anger, receptiveness) to the speakers and the opinions presented in the photos.
It is expected that when participants receive oxytocin they will be more receptive to opposing opinions compared to when they receive the placebo.
Participants may also have differing levels of receptiveness depending on whether the person expressing the opinion comes from their ingroup or outgroup.
|
60-90 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appetite
Time Frame: 60-90 minutes
|
We predict that when participants receive oxytocin they will spend less time looking at photos of food compared to when they receive the placebo.
|
60-90 minutes
|
|
Short vs. Long-Term mating orientation
Time Frame: 60-90 minutes
|
When participants receive oxytocin they will spend more time looking at human infants, less time looking at attractive opposite sex others (especially the bodies of those opposite sex others; additionally, they will exhibit lower testosterone reactivity to images of attractive opposite sex targets and report weaker desires to engage in short-term romantic relationships in general.
|
60-90 minutes
|
|
Peripheral narrowing of attention
Time Frame: 60-90 minutes
|
When participants receive oxytocin they will exhibit less peripheral narrowing on a computerized visual attention task compared to when they receive a placebo.
|
60-90 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Frances Chen, PhD, University of British Columbia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H14-02448
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.